Allen C. Chen

发表

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma

Bohuslav Melichar, Yoshihiko Tomita, Nizar M. Tannir, 2018, The New England journal of medicine.

First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

M. Socinski, D. Carbone, S. Peters, 2017, The New England journal of medicine.

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

N. Agarwal, C. Drake, H. Scher, 2020, European urology.

Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2.

Y. Yatabe, S. Dacic, J. Goldman, 2023, Clinical lung cancer.

A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).

S. Gettinger, F. Shepherd, D. Gerber, 2013 .

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.

S. Gettinger, F. Shepherd, N. Rizvi, 2014 .

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy

S. Gettinger, F. Shepherd, N. Rizvi, 2014 .

NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

M. Socinski, D. Carbone, S. Peters, 2016 .

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma.

R. Motzer, M. McHenry, Allen C. Chen, 2018, The New England journal of medicine.

A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).

J. Mazières, O. Trifan, H. Léna, 2012 .